Blood testing provider Medichecks has showcased its new pathology platform, Plasma, on the Digital Healthcare Present 2023, boosting capability for blood take a look at diagnostics.
Plasma will enable the NHS, GPs, pharmacies, fertility clinics and different healthcare suppliers to satisfy the elevated demand for pathology testing options.
The versatile options enable companions to pick out from a ready-made catalogue of round 100 exams, throughout finger prick and venous blood assortment. Alternatively, exams could be tailored to necessities.
Customers may also achieve entry to over 200 nationwide companion phlebotomy clinics if required, whereas receiving outcomes from the model’s community of accredited laboratories.
Medichecks believes that the brand new platform has the potential to permit the UK healthcare system to evolve by enabling diagnostics-as-a-service.
Dr Sam Rodgers, chief medical officer, Medichecks, stated: “Distant blood testing has the potential to cut back pressure on healthcare techniques and focus service provision to the place it’s most wanted.
“Widening entry to diagnostics and digitising companies is lengthy overdue. COVID-19 demonstrated that the supply of medical care by way of digital channels truly works, and most significantly, is extra accessible and handy for sufferers.
“We all know there have been fears that increasing distant healthcare testing would gasoline well being anxiousness and improve the burden on already stretched companies, however our information reveals the alternative is true.”
A 3-month NHS trial involving the availability of 37,000 CE-marked finger prick blood exams to volunteers in England, resulted in 94% of recipients ranking their expertise with Medichecks nearly as good or glorious.
Supporting versatile diagnostic testing as a service, Plasma is delivered via an intuitive digital portal that may plug into present system APIs. Customisable branding, communications and white label packages can be found via the portal.
Earlier this 12 months Macmillan Most cancers Assist invested in Neutrocheck – a transportable machine and app centred round an at-home finger prick take a look at to detect neutropenic sepsis in most cancers sufferers.